CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)

Conditions:   Metastatic Melanoma;   Renal Cell Carcinoma;   Colon Cancer With MSI-H or dMMR Interventions:   Drug: CD24Fc;   Drug: Ipilimumab;   Drug: Nivolumab Sponsors:   OncoImmune, Inc.;   Huntsman Cancer Institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials